Literature DB >> 21735240

The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR).

Khaled Nassar1, Julia Lüke, Matthias Lüke, Mahmoud Kamal, Effat Abd El-Nabi, Mahmoud Soliman, Martin Rohrbach, Salvatore Grisanti.   

Abstract

BACKGROUND: The cytokine transforming growth factor-ß (TGF-ß) is a pivotal contributor to tissue fibrosis and a key cytokine in the pathogenesis of cellular transdifferentiation, epithelial-mesenchymal transition (EMT), and cell adhesion. This study evaluates the effect of decorin, a naturally occurring TGF-ß inhibitor, in an experimental rabbit model for proliferative vitreoretinopathy (PVR).
METHODS: Traumatic PVR was induced in 50 rabbits divided into ten groups (n = 5). One group (GI) reveals a control with no treatment after trauma. Groups (GII-GIV) consisted of subgroups receiving phacovitrectomy at three different time points; (a) at the time of trauma, (b) 1 week following trauma, and (c) 2 weeks following trauma. GIII and GIV received 100 μg or 200 μg decorin, respectively. PVR severity was scored from 0 to 4. The amount of fibrosis was quantified using JMicroVision© software.
RESULTS: The control group GI developed severe PVR with tractional retinal detachment (TRD); (PVR score ≥2) in four rabbits out of five. Vitrectomy had a positive effect (p < 0.05) on PVR development when preformed immediately, however the developed fibrosis was high. The best results were obtained when surgery was used in conjunction with decorin that reduced both the PVR score and fibrosis development significantly (p < 0.05). Depending on dosage and time of vitrectomy, PVR could be completely avoided (PVR score = 0) in 16 rabbits out of 30. TRD was prevented in 13 rabbits out of 15 in GIII to 14 rabbits out of 15 in GIV. In decorin-treated eyes, vitrectomy outcome was best when preformed at 1 week after trauma. There were no drug-related toxic effects evident on clinical and histopathological examination.
CONCLUSIONS: In conclusion, in this rabbit model of PVR, adjuvant decorin application during vitrectomy effectively reduces fibrosis and TRD development. In conjunction with no obvious histopathological toxicity signs, decorin represents a promising substance to inhibit PVR reactions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21735240     DOI: 10.1007/s00417-011-1730-9

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  63 in total

Review 1.  Controversies in the management of open-globe injuries involving the posterior segment.

Authors:  R A Mittra; W F Mieler
Journal:  Surv Ophthalmol       Date:  1999 Nov-Dec       Impact factor: 6.048

2.  Isolation and cellular localization of the decorin endocytosis receptor.

Authors:  H Hausser; P Wedekind; T Sperber; R Peters; A Hasilik; H Kresse
Journal:  Eur J Cell Biol       Date:  1996-12       Impact factor: 4.492

3.  Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain.

Authors:  B Merle; L Durussel; P D Delmas; P Clézardin
Journal:  J Cell Biochem       Date:  1999-12-01       Impact factor: 4.429

4.  Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon.

Authors:  K G Vogel; M Paulsson; D Heinegård
Journal:  Biochem J       Date:  1984-11-01       Impact factor: 3.857

5.  The role of cellular proliferation in an experimental model of massive periretinal proliferation.

Authors:  D M Fastenberg; K R Diddie; K Dorey; S J Ryan
Journal:  Am J Ophthalmol       Date:  1982-05       Impact factor: 5.258

6.  Changing concepts of failures after retinal detachment surgery.

Authors:  W F Rachal; T C Burton
Journal:  Arch Ophthalmol       Date:  1979-03

7.  Natural history of penetrating ocular injury with retinal laceration in the monkey.

Authors:  H T Hsu; S J Ryan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

8.  Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney.

Authors:  Y Isaka; D K Brees; K Ikegaya; Y Kaneda; E Imai; N A Noble; W A Border
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

9.  Experimental retinal detachment in the rabbit. Penetrating ocular injury with retinal laceration.

Authors:  H T Hsu; S J Ryan
Journal:  Retina       Date:  1986 Winter-Spring       Impact factor: 4.256

10.  Fibronectin-mediated adhesion of fibroblasts: inhibition by dermatan sulfate proteoglycan and evidence for a cryptic glycosaminoglycan-binding domain.

Authors:  K Lewandowska; H U Choi; L C Rosenberg; L Zardi; L A Culp
Journal:  J Cell Biol       Date:  1987-09       Impact factor: 10.539

View more
  24 in total

Review 1.  The stereotypical molecular cascade in neovascular age-related macular degeneration: the role of dynamic reciprocity.

Authors:  D Kent
Journal:  Eye (Lond)       Date:  2015-07-31       Impact factor: 3.775

2.  Expression of IGFBP-6 in a proliferative vitreoretinopathy rat model and its effects on retinal pigment epithelial cell proliferation and migration.

Authors:  Hong-Mei Zhao; Min-Jie Sheng; Jing Yu
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

Review 3.  Müller glia: Stem cells for generation and regeneration of retinal neurons in teleost fish.

Authors:  Jenny R Lenkowski; Pamela A Raymond
Journal:  Prog Retin Eye Res       Date:  2014-01-08       Impact factor: 21.198

4.  Intravitreal decorin preventing proliferative vitreoretinopathy in perforating injuries: a pilot study.

Authors:  Abdussalam M Abdullatif; Tamer A Macky; Mona M Abdullatif; Khaled Nassar; Salvatore Grisanti; Hassan A Mortada; Mahmoud M Soliman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-20       Impact factor: 3.117

5.  The influence of systemic renin-angiotensin-inhibition on ocular cytokines related to proliferative vitreoretinopathy.

Authors:  Robert Hoerster; Sascha Fauser; Claus Cursiefen; Bernd Kirchhof; Ludwig M Heindl
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-09       Impact factor: 3.117

6.  Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy.

Authors:  B N M K Khanum; R Guha; V P Sur; S Nandi; S K Basak; A Konar; S Hazra
Journal:  Eye (Lond)       Date:  2017-03-17       Impact factor: 3.775

Review 7.  [Pharmacological approach to treatment of proliferative vitreoretinopathy].

Authors:  C S Priglinger; S Priglinger
Journal:  Ophthalmologe       Date:  2013-10       Impact factor: 1.059

8.  Upregulation of TGF-ß1 in experimental proliferative vitreoretinopathy is accompanied by epithelial to mesenchymal transition.

Authors:  Robert Hoerster; Philipp S Muether; Sarah Vierkotten; Manuel M Hermann; Bernd Kirchhof; Sascha Fauser
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-17       Impact factor: 3.117

Review 9.  Pharmacotherapy as an adjunct to vitrectomy.

Authors:  Victor M Villegas; Mónica P González; Audina M Berrocal; Timothy G Murray
Journal:  Ther Adv Ophthalmol       Date:  2021-05-23

10.  Sustained dasatinib treatment prevents early fibrotic changes following ocular trauma.

Authors:  Shunichiro Ueda; Betty M Nunn; Rajat Chauhan; Kevin McDonald; Henry J Kaplan; Martin G O'Toole; Shigeo Tamiya
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-01-08       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.